All immunotherapy articles
-
NewsHow aggressive breast cancer evades the immune system
Researchers in China have discovered a previously unknown mechanism that allows aggressive breast cancers to avoid immune attack, while simultaneously exposing a weakness that could make these tumours especially responsive to existing immunotherapy treatments.
-
NewsNew CAR-NKT treatment destroys metastatic pancreatic tumours
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments.
-
NewsWhy TIGIT cancer therapies work in monkeys but not humans
A new study reveals that TIGIT, a key immune checkpoint targeted by cancer drugs, behaves differently in rhesus macaques and humans, suggesting current animal tests may be misleading drug development.
-
NewsTargeting p300 may boost immunotherapy in kidney cancer
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
-
NewsNew CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
-
NewsSenolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
-
NewsAnti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
-
NewsMelanoma research: targeted drug duo reactivates immune response
Researchers at Sutter’s California Pacific Medical Center have discovered a potential new treatment strategy for melanoma patients who stop responding to immunotherapy.
-
ArticleLupus reimagined: targeting the cause, not just the symptoms
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
-
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
-
ArticleWhy most T-cell engagers fail - and how to fix it
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
-
NewsFuelling immunity: glucose helps T cells fight cancer better
A new study from the Van Andel Institute shows that glucose not only fuels T cells but also strengthens their internal signalling and cancer-fighting capabilities –offering a potential route to improved immunotherapies.
-
NewsDual CAR-T cell therapy targets T-ALL with precision
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
-
NewsDual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
-
NewsBCG alters bone marrow to strengthen anti-cancer response
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
-
NewsHerpes virus protein boosts T cell power against cancer
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
-
NewsWhy ATP signalling might change melanoma for good
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
-
NewsScientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
-
ArticlePioneering cellular therapies for age-related diseases
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
-
NewsBacteria-boosted nanoparticles offer a triple threat against cancer
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.